MS treatment: FDA-approved biosimilar could bring down costs
The Food and Drug Administration has recently announced the approval of the first biosimilar treatment for multiple sclerosis, called Tyruko, which provides a potentially more cost-effective alternative to Tysabri.
Source: medicalnewstoday.com